


## Immunodex Announces Verifiable Immunity Passports to Reboot the Economy during COVID-19

Hong Kong, 22 April, 2020 - Immunodex is proud to announce the launch of its Verifiable Immunity Passport (VIP), a digital proof-of-health that allows immune individuals to return to everyday life.

Immunodex, a health technology company, believes its Verifiable Immunity Passport (VIP) will ease quarantine and isolation restrictions by proving the health status of any individual tested for COVID-19. Immune individuals can be authorized the freedom of work, travel or other forms of mobility, while governments, healthcare systems and businesses can resume operations safely. This will put society on the path to economic recovery until a vaccine is available.



*Immunodex's Verifiable Immunity Passport proves an individual's health status with regards to COVID-19 in a secure, tamper-proof and privacy-preserving way.*

"We believe that tracking immunity for essential workers on the frontline could potentially be a powerful reassurance tool to solidify a safe return to work," explained **Dr. Anna Der**, a frontline physician and Chief Medical Officer of Immunodex. "However, since each decision maker has its own definitions and policies for immunity, and the accuracy of testing is an ongoing challenge, we propose a system that holds companies accountable for their test kits and lab tests, and faithfully reports on the health status of individuals while genuinely respecting their privacy. Without these, decision makers cannot enforce their policies."

Developed by healthcare professionals and cryptography researchers from the Hong Kong Blockchain Society, the VIP is a collection of certificates issued by an attesting party (such as a health authority or health care professional) that verifies the holder of the VIP has fulfilled conditions of attaining a level of immunity to a disease (via diagnostic assessment or vaccination if available). Immunodex's VIP conforms with the World Wide Web Consortium (W3C) Verifiable Credentials guidelines, outlining a recent technology that requires blockchain and advanced cryptography to make digital identities auditable, fraud-proof and therefore trustworthy to any verifying party.

## How Immunodex's Verifiable Immunity Passport (VIP) Works



### Immunodex Operator Network

Various registries and databases exchange information, under a neutrally governed business framework



*A brief schematic of how Immunodex's Verifiable Immunity Passport works*

Based on several years of proprietary cryptographic research, Immunodex's VIP is built to be provably secure and privacy-preserving. All data registered onto the certificates is owned by the holder (patient) and only revealed to other verifying parties upon consent. Immunodex may further enhance privacy of all parties with integrated zero-knowledge proof cryptography and anonymous credential techniques. Their verifiable credentials technology is EU GDPR compliant.

The VIP's digital certificates are designed to be issued by authorized healthcare institutions who would administer and generate results of reverse transcription polymerase chain reaction (RT-PCR, i.e. "swab") and lateral flow immunoassay ("antibody") tests, the clinical diagnostic tools currently

available. The VIP also has an option to generate cryptographic declarations based on at-home tests that biomedical manufacturers are planning to release. Additionally, Immunodex offers health authorities the ability to coordinate mass screening programmes — patients can schedule testing at a designated site and will be automatically updated with the results in their VIP. Immunodex's technology is capable of anonymizing collected epidemiological datasets to support government policies for controlling the pandemic, while simultaneously preparing for future public health threats.

The VIP is available for individuals as a secure mobile app with an intuitive, user-friendly interface. Upon the holder's consent, the relevant information is exchanged via scanning of a QR code. For healthcare providers, Immunodex's "plug-and-play" solution can be readily integrated into most clinical settings and government agencies, including with cross-border policies.

Digital immunity certificates have received support by prominent technology figures, such as Bill Gates during an ["Ask-Me-Anything" session on Reddit](#) last month. To a question one user asked about how businesses could keep running while complying with social distancing rules, he answered,

*"The question of which businesses should keep going is tricky. Certainly food supply and the health system. We still need water, electricity and the internet. Supply chains for critical things need to be maintained. Countries are still figuring out what to keep running.*

*Eventually we will have some digital certificates to show who has recovered or been tested recently or when we have a vaccine who has received it."*

The US, UK and German governments have been reported to be working on some form of immunity credential to allow recovered, antibodies-positive people, estimated to be anywhere from 2.8%<sup>1</sup> to 15%<sup>2</sup> of the population, to return to the workforce.

Immunodex was founded by a doctor-led team of experts in medicine, blockchain cryptography and health technology from Hong Kong, Canada and Europe. This product began as a winning project in the 2019 International Blockchain Olympiad competition and has since been collaborating with non-profit organizations in Hong Kong. It is expanding globally to deliver the next generation of user-centric verifiable credentials for immunizations, including vaccinations.

— END —

## CONTACTS

Chloe Chan  
Public Relations  
chloe.chan@immunodex.com

## ABOUT IMMUNODEX

Immunodex is a healthtech company in Hong Kong that works with academics, corporate and non-profit entities to deliver verifiable credential products for healthcare applications around the world.

## References

1. Bendavid E, Mulaney B, Sood N, et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California. *MedRxiv* 2020 [Ahead of press].
2. Vogel G. Antibody surveys suggesting vast undercount of coronavirus infections may be unreliable. *Science* 2020.